Document:

Note Extension and Modification Agreement, effective December 31,1994

 Exhibit 10.17 
 NOTE EXTENSION AND MODIFICATION AGREEMENT 
 THIS NOTE AND EXTENSION MODIFICATION AGREEMENT
(“Agreement”) is entered into by and between JILCO INDUSTRIES, INC., a California corporation (“Payor”) and LEONARD M. ROSS, a California resident (“Payee”). 
 Payor and Payee do hereby mutually acknowledge and agree that Payor is presently liable for the indebtedness represented by a certain promissory note
payable to Payee dated December 18, 1987 in the original principal amount of FORTY THOUSAND DOLLARS ($40,000.00) (“Note”) with interest accruing on the unpaid principal balance at the rate of 9% per year. Payor and Payee
previously agreed to extend the initial maturity date of December 31, 1989 to December 31, 1991 and subsequently agreed to extend the second maturity date of December 31, 1991 to December 31, 1994. Said Note was not paid on
December 31, 1994 and interest on the unpaid principal balance has continued to accrue through July 31, 2006. Payor has requested Payee to again extend the maturity date of said Note and Payor is willing to do so. 
 NOW, THEREFORE, FOR VALUABLE CONSIDERATION IN HAND 
 RECEIVED, the parties hereto, and each of them, do hereby agree that as of the date hereof, the unpaid principal portion of the Note and all unpaid accrued interest, if any, shall be all due and payable on July 31, 2007. 
 Nothing contained herein shall be deemed to affect the obligation of Payor regarding the payment of interest accrued on the Note through the date hereof,
or to affect any obligations of Payor under the Note, except as set forth herein. 
 IN WITNESS WHEREOF, the parties hereto, and each of
them, have executed this Agreement as of the date set forth below but effective as of the 31st day of December, 1994. 
  

							
		 	    JILCO INDUSTRIES, INC.	 	
		 	    a California corporation	 	
				
	 Date:    August  29, 2006
	 	By:	 	 /s/ Martha J. Kretzmer
	 	
		 	    Martha J. Kretzmer	 	
		 	    President	 	
		 	     “Payor”
  
	 	
				
	 Date:    August  29, 2006
	 	By:	 	 /s/ Leonard M. Ross
	 	
		 	Leonard M. Ross	 	
		 	“Payee”Notice of Breach and Demand for Dispute Resolution

 Exhibit 10.1 
 NOTICE OF BREACH AND DEMAND FOR DISPUTE RESOLUTION 
 We make reference to the
Clinical Development and License Agreement, dated as of July 14, 2005, among BioDelivery Sciences International, Inc., (“BDSI”), Clinical Development Capital LLC (together with its successors and assigns, including, without
limitation, CDC IV, LLC, collectively, “CDC”), and Arius Pharmaceuticals, Inc. (such agreement, as amended, the “CDLA”). All capitalized terms used but not defined herein shall have the meanings assigned to such
terms in the CDLA. 
 BDSI hereby gives notice to CDC that: (i) CDC is in material breach of the CDLA and
(ii) therefore, BDSI demands that the parties immediately proceed to address CDC’s material breaches in accordance with the provisions of Articles 2 and 11 and all other applicable provisions of the CDLA and any related agreements between
CDC, BDSI and any affiliates of BDSI. 
 CDC has breached the CDLA in several ways to the significant detriment of BDSI and
its stockholders, including, without limitation: 
 1. CDC violated the CDLA when, without knowledge or consent of BDSI, CDC,
using proprietary and confidential information of BDSI protected by the terms of the CDLA, made an offer in May 2006 to acquire, directly from BDSI’s licensor, the remaining interest in BEMATM Fentanyl and/or the BEMATM technology for its own financial benefit. In so doing, CDC: (i) used BDSI confidential information in violation of Article 7 of the CDLA, (ii) materially and adversely interfered with BDSI’s contractual relationship
with its licensor and (iii) caused BDSI to expend significant and unnecessary financial and other resources to acquire the BEMATM technology for itself. 
 2. CDC has repeatedly and willfully refused to: (i) convene or
designate its representatives to the Development Committee, despite BDSI’s numerous requests to do so and (ii) respond to repeated requests from BDSI for collaboration with BDSI management on the BEMATM Fentanyl program as provided for under the CDLA. 
 3. CDC has willfully refused (despite BDSI’s requests) to comply with the negotiated dispute resolution provisions of the CDLA. In so doing, CDC has caused BDSI to expend significant and unnecessary financial and
other resources in defending itself from CDC’s unwarranted attacks on BDSI’s management and board of directors. 
 BDSI hereby demands that CDC immediately comply with all provisions of the CDLA and related agreements and further demands that the foregoing and all claims under the CDLA be submitted immediately for resolution pursuant to the dispute
resolution mechanisms set forth in the CDLA. BDSI reserves all its rights and remedies against CDC, and its officers, directors, members, managers, controlling persons and affiliates, including with respect to breaches not enumerated. 
  

			
	BIODELIVERY SCIENCES INTERNATIONAL, INC.
		
	By:	 	 /s/ Mark A. Sirgo

	Name:	 	Mark A. Sirgo
	Title:	 	President and Chief Executive OfficerNotice of Breach and Termination

 Exhibit 10.1 
 NOTICE OF BREACH AND TERMINATION 
 We make reference to the Clinical
Development and License Agreement dated as of July 14, 2005 among BioDelivery Sciences International, Inc, (“BDSI”), Clinical Development Capital LLC (together with its successors and assigns,
“CDC”), and Arius Pharmaceuticals, Inc. (such agreement, as amended, the “CDLA”). 
 CDC hereby gives notice to BDSI that (i) BDSI is in material breach of the CDLA and (ii) CDC is terminating the CDLA pursuant to Section 10.2 of the CDLA. BDSI’s breaches are not curable, such that the termination of the
CDLA is effective immediately. If one or more of these breaches are subject to cure, then this Notice of Breach and Termination (“Notice”) also serves as a notice for purposes of starting any applicable cure period under the
CDLA. 
 The natures of BDSI’s defaults are as follows: 
  

	 	1.	 On August 15 2006, BDSI submitted to the United States Food and Drug Administration (“FDA”), without CDC’s approval, an amended
agenda that changed the protocols and end-point of the clinical trials in violation of, inter alia, Sections 2.1 and 2.3 of the CDLA. 

  

	 	2.	 On July 26, 2006, BDSI was notified by the Research Advisory Panel of California that BDSI had failed to comply with applicable laws and protocols in
obtaining informed patient consents, which failures are in violation of, inter alia, Sections 4.1 and 4.5 of the CDLA. 

  

	 	3.	 BDSI failed until August 22, 2006 to notify CDC of the failures to comply identified in item 2 above, in violation of, inter alia, Section 4.5
of the CDLA. 

 CDC hereby demands that BDSI immediately comply with its obligations under
Section 10.5 of the CDLA, including its obligations to transfer the specified assets and rights to CDC. CDC reserves all its rights and remedies against BDSI and its officers and directors, including with respect to breaches not enumerated.

  

			
	CDC IV, LLC,
	As successor and assign of Clinical
	Development Capital LLC
		
	By:	 	 /s/ David R. Ramsay

	Name:	 	David R. Ramsay
	Title:	 	Authorized SignatoryAmendment No. 6 to Employees Stock Ownership Plan

 Exhibit 10(d)(6) 
 AMENDMENT No. 6 TO 
 RICHARDSON ELECTRONICS, LTD. EMPLOYEES STOCK OWNERSHIP PLAN

 (As Amended and Restated Effective June 1, 1997) 
 RICHARDSON ELECTRONICS, LTD., a Delaware corporation, hereby further amends the Richardson Electronics, Ltd. Employees Stock Ownership Plan, as
previously amended and restated effective June 1, 1997 and as thereafter further amended (the “Plan”), as follows effective October 1, 2005. 
  

	 	1.	The following sentence is added to Section 2.16 of the Plan: 

 Notwithstanding the preceding sentence, the Entry Date shall be October 1, 2005 for any individual formerly employed by Image Systems Corporation who became an Employee on said date and who satisfied the requirements of
Section 3.1(a), taking into account Section 2.18(c) of the Plan, as of said date. 
  

	 	2.	The following sentence is added to Section 2.18(c) of the Plan: 

 Service by an individual on behalf of Image Systems Corporation before he became an Employee shall be considered service on behalf of the Employer for purposes of this Section 2.18, effective October 1, 2005
and including service prior to that date. 
 Dated November 22, 2005. 
  

			
	RICHARDSON ELECTRONICS, LTD.
		
	By:	 	     /s/    William G.
Seils        

		 	     William G. Seils

		 	     Senior Vice President,

		 	     General Counsel and SecretaryFirst Amendment to Purchase and Sale Agreement

 Exhibit 10 (ai)(1) 
 FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT 
 This First Amendment to Purchase and Sale Agreement is dated as of
this 16th date of December, 2005 between RICHARDSON ELECTRONICS, LTD., a Delaware corporation (“Seller”) and TAB Construction Company, an Illinois corporation (“Purchaser”). 
 R E C I T A L S 
 WHEREAS, Seller is the owner of fee simple title, free and clear of all liens and encumbrances except for the Permitted Exceptions, of that certain to real estate located in the City of Geneva, Kane County, Illinois, commonly known as 715
Hamilton Street, Geneva, Illinois and has executed a Purchase and Sale Agreement dated August 4, 2005 with Purchaser in the connection with the sale of the Property as defined therein to Purchaser (the “Purchase Agreement”);

 WHEREAS, Seller and Purchaser have decided to amend the Purchase Agreement. 
 NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, parties shall hereby agree as follows:

 1.    DUE DILIGENCE PERIOD. Notwithstanding anything to the contrary contained in the Purchase
Agreement, the parties have agreed that the Due Diligence Period be extended until January 30, 2006; provided that, such Due Diligence Period shall be extended only with respect to investigation related to the following items, the Purchaser
being satisfied with the Property on all other conditions: 
  

	 	•	 	Wipe test for Thorium (arising out of State of Illinois requirement to remove location from Richardson Electronics license); 

  

	 	•	 	Purchaser’s ability to successfully negotiate an agreement with the Village of Geneva to acquire the 25 foot strip owned by the Village and adjoining the Property, to the East;

 and provided that, Purchaser diligently pursues such investigation. 
 2.    CLOSING DATE. Notwithstanding anything to the contrary contained in the Purchase Agreement, the parties have
agreed to close the transaction on or before February 15, 2006. Time is of the essence with respect to said closing date due to Seller’s the desire to close the transaction by the end of Seller’s fiscal third quarter. 
 4.    FULL FORCE AND EFFECT. As otherwise set forth herein, the Purchase Agreement remains in full force and effect.

 5.    COUNTERPARTS. This Amendment may be executed in counterparts, both of which when taken together
shall constitute a single original. 

 IN WITNESS WHEREOF, the parties have executed this First Amendment as of the date and year first
written above. 
 SELLER: 
  

			
	 Richardson Electronics, Ltd., a Delaware corporation

	
	 /s/ Edward J. Richardson

	 By:
	 	Edward J. Richardson
	 Title: CEO

 PURCHASER: 
  

			
	 TAB Construction Company

	
	 /s/ Tracy A. Burnidge

	 By:
	 	Tracy A. Burnidge
	 Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]